Search results
Showing 691 to 705 of 1305 results for long term conditions
Cochlear implants for children and adults with severe to profound deafness (TA566)
Evidence-based recommendations on cochlear implants for children and adults with severe to profound deafness.
Secukinumab for treating active non-radiographic axial spondyloarthritis (TA719)
Evidence-based recommendations on secukinumab (Cosentyx) for treating active non-radiographic axial spondyloarthritis in adults.
This guideline covers road-traffic-related air pollution and its links to ill health. It aims to improve air quality and so prevent a range of health conditions and deaths.
Evidence-based recommendations on alteplase (Actilyse) for treating acute ischaemic stroke in adults.
Evidence-based recommendations on intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure in people with motor neurone disease. This involves implanting electrodes into the diaphragm to make it contract. This gradually strengthens the diaphragm and may eventually help the person to breathe without a ventilator.
Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy and docetaxel for hormone-sensitive metastatic prostate cancer in adults.
Evidence-based recommendations on cinacalcet (Mimpara) for treating secondary hyperparathyroidism in people with end-stage renal disease who are on dialysis.
Focal therapy using cryoablation for localised prostate cancer (HTG284)
Evidence-based recommendations on focal therapy using cryoablation for localised stage prostate cancer. This involves using freezing (cryotherapy) needles to find and destroy only the cancerous part of the prostate.
View recommendations for HTG284Show all sections
Sections for HTG284
Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation (HTG752)
Evidence-based recommendations on transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation. This involves implanting a replacement valve inside the faulty native valve.
View recommendations for HTG752Show all sections
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)
Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.
This quality standard covers the period before, during and after a young person moves from children’s to adults’ services in all settings where transitions from children’s to adults’ health or social care services take place. It covers all young people (aged up to 25) using children’s health and social care services who are due to make the transition to adults’ services. This includes young people with mental health problems, disabilities and long-term, life-limiting or complex needs, rare diseases and those in secure settings or under the care of local authorities. It describes high-quality care in priority areas for improvement.
View quality statements for QS140Show all sections
Sections for QS140
- Quality statements
- Quality statement 1: Planning transition
- Quality statement 2: Coordinated transition plan
- Quality statement 3: Annual meeting
- Quality statement 4: Named worker
- Quality statement 5: Meeting a practitioner in adults' services
- Quality statement 6: Missed initial appointments after transfer to adults' services
- Update information
Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.
This guideline covers helping adults and young people over 16 who are dependent on opioids to stop using drugs. It aims to reduce illicit drug use and improve people’s physical and mental health, relationships and employment.
This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over, including people with type 2 diabetes. It aims to reduce the risk of cardiovascular problems such as heart attacks and strokes by helping healthcare professionals to diagnose hypertension accurately and treat it effectively.
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma after disease progression with ipilimumab in adults.